---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-044623"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:13:17.791427+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023

## Summary
- Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.
- Compensation: $350k base salary, 40% target bonus; inducement equity of 100,000 options at $4.79 (4-year vest) and 100,000 performance RSUs.
- Performance RSUs: 50,000 vest upon extending cash runway 24 months; 50,000 vest upon stock price reaching $10.00 for 10 days VWAP.
- Background: Ballantyne was CFO of OncXerna, Orchestra BioMed, Cerecin; raised millions in equity and structured >$200M partnership.

## SEC filing metadata
- accession: 0001104659-23-044623
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/tm2312468d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-044623
- JSON: https://secwatch.observer/filing/0001104659-23-044623.json
- Plain text: https://secwatch.observer/filing/0001104659-23-044623.txt

## Key facts
- Executive change
  Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm
- Executive change
  C. Evan Ballantyne was appointed as Chief Financial Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.